Identifying factors that predict survival in aggressive meningiomas
Analysis of Predictive Factors for Overall and Progression-free Survival After Neurosurgery for Atypical or Anaplastic Meningioma
This study is trying to find out what factors can help predict how long patients with aggressive meningiomas will survive after surgery.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Fondazione Policlinico Universitario Agostino Gemelli IRCCS Academic / other |
| Locations | 1 site (Rome) |
| Trial ID | NCT05793034 on ClinicalTrials.gov |
What this trial studies
This study aims to collect clinical and molecular data from patients who have undergone surgery for grade 2 or grade 3 meningiomas. The investigators will analyze various biological markers, including ICH, PCR, NGS, and methylome data, to identify predictive factors for recurrence and survival post-surgery. By focusing on these aggressive forms of meningioma, the study seeks to enhance understanding of patient outcomes and improve treatment strategies.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have been operated on for atypical (grade 2) or anaplastic (grade 3) meningiomas between 1999 and 2019.
Not a fit: Patients who were lost to follow-up after surgery will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide critical insights that help predict patient survival and recurrence rates, leading to more personalized treatment plans.
How similar studies have performed: While this approach is focused on aggressive meningiomas, similar studies in other tumor types have shown success in identifying predictive factors for patient outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patient operated for atypical (grade 2) meningioma; or 2. Patient operated for anaplastic (grade 3) meningioma; 3. Timeframe for surgery, 1999-2019 Exclusion criteria 1\) Patient lost at follow-up
Where this trial is running
Rome
- Fondazione Policlinico Universitario A. Gemelli IRCCS — Rome, Italy (Recruiting)
Study contacts
- Study coordinator: Alessandro Olivi, MD
- Email: alessandro.olivi@policlinicogemelli.it
- Phone: +39 06 3015 4120
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.